Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage IIIA)

Bačić,Ivan; Karlo,Robert; Zadro,Ana  Šoštarić; Zadro,Zvonko; Skitarelić,Neven; Antabak,Anko

doi:10.3892/ol.2017.7576

Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage IIIA)

Authors:
- Ivan Bačić
- Robert Karlo
- Ana Šoštarić Zadro
- Zvonko Zadro
- Neven Skitarelić
- Anko Antabak
View Affiliations

Affiliations: Department of Surgery, Zadar General Hospital, Zadar 23000, Croatia, Department of Radiology, University Hospital for Infectious Diseases, Zagreb 10000, Croatia, Department of Surgery, University Hospital, Sveti Duh, University of Zagreb, Zagreb 10000, Croatia, Department of Health Studies, University of Zadar, Zadar 23000, Croatia, Surgery Clinic, University Hospital Centre Zagreb, Zagreb 10000, Croatia
Published online on: December 8, 2017 https://doi.org/10.3892/ol.2017.7576
Pages: 2335-2339
Copyright: © Bačić et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate angiogenesis by determining the micro vascular density (MVD) and the expression of vascular endothelial growth factor (VEGF‑A) in advanced non‑small cell lung cancer (NSCLC) tumor samples, and to analyze their associations with clinical parameters and survival. Tumor tissue specimens of fifty patients (41 males and 9 females), who underwent radical surgical treatment for NSCLC in stage IIIA (T1‑3N2) were collected for immunohistochemical analysis. MVD evaluation was performed using an anti‑CD31 monoclonal antibody and VEGF‑A expression using a polyclonal anti‑VEGF‑A antibody. The results were associated with two‑year survival. Statistical analysis revealed significant associations in the level of angiogenesis (high MVD) and shorter survival of patients with NSCLC (P=0.0007). VEGF‑A expression showed no association with micro vascular density (P=0.51) or survival (P=0.68). There was no significant association between MVD and VEGF‑A. The measurable, clinical MVD parameters could be used as a reliable prognostic factor for the survival of patients with advanced NSCLC.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu Y, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
2	Pisters KM and Darling G: The IASLC lung cancer staging project: ‘The Nodal Zone’. J Thorac Oncol. 2:583–584. 2007. View Article : Google Scholar : PubMed/NCBI
3	Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 147:9–19. 1995.PubMed/NCBI
4	Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol. 3:65–71. 1992.PubMed/NCBI
5	Cox G, Jones JL, Walker RA, Steward WP and O'Byrne KJ: Angiogenesis and non-small cell lung cancer. Lung Cancer. 27:81–100. 2000. View Article : Google Scholar : PubMed/NCBI
6	Fox SB, Gatter KC and Harris AL: Tumour angiogenesis. J Pathol. 179:232–237. 1996. View Article : Google Scholar : PubMed/NCBI
7	Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B and Tonin G: Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 57:591–597. 2004. View Article : Google Scholar : PubMed/NCBI
8	Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF and Brown LF: Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest. 74:1105–1115. 1996.PubMed/NCBI
9	Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ and Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 56:172–181. 1996.PubMed/NCBI
10	Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T and Sowa M: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 77:858–863. 1996. View Article : Google Scholar : PubMed/NCBI
11	Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55:3964–3968. 1995.PubMed/NCBI
12	Maharaj AS, Saint-Geniez M, Maldonado AE and D'Amore PA: Vascular endothelial growth factor localization in the adult. Am J Pathol. 168:639–648. 2006. View Article : Google Scholar : PubMed/NCBI
13	Ferrera N: Vascular endothelial growth factor. Trends Cardiovasc Med. 3:244–250. 1993. View Article : Google Scholar : PubMed/NCBI
14	Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, Lafitte JJ, Mascaux C and Sculier JP: The role of microvessel density on the survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer. 87:694–701. 2002. View Article : Google Scholar : PubMed/NCBI
15	Kadota K, Huang CL, Liu D, Ueno M, Kushida Y, Haba R and Yokomise H: The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer. 44:1057–1067. 2008. View Article : Google Scholar : PubMed/NCBI
16	Fontanini G, Vignati S, Boldrini L, Chinè S, Silvestri V, Lucchi M, Mussi A, Angeletti CA and Bevilacqua G: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res. 3:861–865. 1997.PubMed/NCBI
17	Han H, Silverman JF, Santucci TS, Macherey RS, d'Amato TA, Tung MY, Weyant RJ and Landreneau RJ: Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 8:72–79. 2001. View Article : Google Scholar : PubMed/NCBI
18	International Association for the Study of Lung Cancer and Peter GoldstrawIASLC Staging Manual in Thoracic Oncology. Orange Park: Editorial Rx Press; 2009
19	Janković M, Samarzija M, Jakopović M, Kulis T and Znaor A: Trends in lung cancer incidence and mortality in Croatia, 1988–2008. Croat Med J. 53:93–99. 2012. View Article : Google Scholar : PubMed/NCBI
20	Matsuyama K, Chiba Y, Sasaki M, Tanaka H, Muraoka R and Tanigawa N: Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. Ann Thorac Surg. 65:1405–1409. 1998. View Article : Google Scholar : PubMed/NCBI
21	Macchiarini P, Fontanini G, Hardin MJ, Squartini F and Angeletti CA: Relation of neovascularization to metastasis of non-small cell lung cancer. Lancet. 340:145–146. 1992. View Article : Google Scholar : PubMed/NCBI
22	Giatromanolaki A, Koukourakis MI, Theodossiou D, Barbatis K, O'Byrne K, Harris AL and Gatter KC: Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. Clin Cancer Res. 3:2485–9224. 1997.PubMed/NCBI
23	Angeletti CA, Lucchi M, Fontanini G, Mussi A, Chella A, Ribechini A, Vignati S and Bevilacqua G: Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence. Cancer. 78:409–415. 1996. View Article : Google Scholar : PubMed/NCBI
24	Chandrachud LM, Pendleton N, Chisholm DM, Horan MA and Schor AM: Relationship between vascularity, age and survival in non-small-cell lung cancer. Br J Cancer. 76:1367–1375. 1997. View Article : Google Scholar : PubMed/NCBI
25	Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M and Rilke F: Immunocytochemical markers in stage I lung cancer: Relevance to prognosis. J Clin Oncol. 15:2858–2865. 1997. View Article : Google Scholar : PubMed/NCBI
26	Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y and Yasumoto K: Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg. 115:1007–1014. 1998. View Article : Google Scholar : PubMed/NCBI
27	Iwasaki A, Kuwahara M, Yoshinaga Y and Shirakusa T: Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eu J Cardio-Thoracic Surg. 25:443–448. 2004. View Article : Google Scholar
28	Bonnesen B, Pappot H, Holmstav J and Skov BG: Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis. Lung Cancer. 66:314–318. 2009. View Article : Google Scholar : PubMed/NCBI
29	Yano T, Tanikawa S, Fujie T, Masutani M and Horie T: Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer. 36:601–609. 2000. View Article : Google Scholar : PubMed/NCBI
30	Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C and Brambilla E: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival. J Pathol. 188:369–377. 1999. View Article : Google Scholar : PubMed/NCBI